Respiratory syncytial virus (RSV) infections in hematopoietic cell transplant (HCT) recipients and hematological malignancy (HM) patients

- **Incidence of RSV infections**
  - HCT recipients: 5%-49%; HM patients: ~30%

- **Risk factors**
  - Progression from URTI to LTRI → higher mortality rate

- **Long-term complication**
  - Reduction in pulmonary function

- **Current treatments**
  - Ribavirin and immuno-modulators (e.g. intravenous immunoglobulins or RSV monoclonal antibodies (palivizumab))

Khawaja and Chemaly. Haematologica, 2019